Medications for Opioid Use Disorder (MOUD) Infographic
This infographic shows different types of medications approved by the U.S. Food and Drug Administration for opioid overdose, withdrawal, and addiction.
If you do not find what you are looking for try searching with a different term or contact us.
This infographic shows different types of medications approved by the U.S. Food and Drug Administration for opioid overdose, withdrawal, and addiction.
This poster identifies some of the most common harm reduction methods in an attempt to normalize the term “harm reduction” and broaden the definition.
This activity focuses on the critical evaluation and management of opioid use disorder (OUD), a pervasive condition significantly diminishing patients’ quality of life and contributing to a widespread epidemic in the United States.
There are strategies that can assist community leaders, local and regional organizers, non-profit groups, law enforcement, public health, and members of the public in understanding and navigating effective ways to prevent opioid overdose in their communities. Use this information as a reference for evidence-based practices that have been successfully implemented in the U.S.
Implementing an effective Crisis Response System benefits individuals, families and communities. This training will provide an overview of the goals and strategies to consider when designing and implementing an effective Crisis Response System while also considering how to structure services and approaches to best meet the needs of individuals who experience a mental health crisis and how to respond to individuals at risk of suicide.
The USA is experiencing increases in methamphetamine use and methamphetamine-related or attributed deaths. In the current study, we explore qualitative narratives of methamphetamine overdose and strategies used by people who use drugs to reduce the undesirable effects associated with methamphetamine use.
Between February 2017 and May 2018, we conducted qualitative interviews with 45 PWUDs who had seen an overdose, recruited from San Diego County, California, using outreach, referrals, and flyers…
he current epidemic of opioid overdoses in the United States necessitates a robust public health and clinical response. We described patterns of non-fatal opioid overdoses (NFOODs) in a small western region using data from the 9-1-1 Computer Assisted Dispatch (CAD) record and electronic Patient Clinical Records (ePCR) completed by EMS responders. …
For new members of 12-step programs like Alcoholics Anonymous and Narcotics Anonymous, naloxone can still seem like a symbol of drug use, according to new research. This can cause some people looking to kick drugs through these large abstinence-based fellowships—NA, for example, holds 70,000 weekly meetings in 144 countries, according to a 2018 survey—to decline to carry the overdose-reversal drug, seeing it as a relic of a past life.
The Mobile Emergency Recovery Intervention Trial (MERIT) is a grant-funded research study that is evaluating the effectiveness and long-term outcomes of an ER-based intervention for opioid overdose patients treated in Nevada’s Emergency Departments (EDs). The research is currently ongoing.
Individuals with opioid use disorder being released from prison are at particularly high risk for fatal overdose, yet virtually no U.S. correctional facilities initiate or continue medications for addiction treatment that would protect people against overdose following release from prison. This study explored whether a novel program in the state of Rhode Island that continued inmates’ opioid use disorder medications led to decreased drug overdoses.
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose…
“Gambling disorder (GD) is a psychiatric condition featuring recurrent, maladaptive gambling behavior that leads to clinically significant distress. GD was reclassified recently into the “Substance-Related and Addictive Disorders” group of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)1, a first for a behavioral addiction” (Menchon, et al., 2018; American Psychiatric Association, 2013). While gambling is a harmless activity for most people who gamble, some – approximately one percent of the U.S. population – develop severe gambling disorder (Kessler, et al., 2008; Alegria, et al., 2009; Shaffer, et al., 1999). Some populations have higher rates of disordered gambling, such as youth and young adults, 6-9%, some ethnic and racial minorities, and those with other addictive behaviors or mental health disorders (Barnes, et al., 2010; Barry, et al., 2011; Kessler, et al., 2008; Petry, et al., 2005).
SAMHSA’s practitioner training offers tools, training, and technical assistance to practitioners in the fields of mental health and substance use disorders.
Substance Use disorders in Older Adults is a growing problem not only in the United States, but throughout the developed world. This may be particularly relevant among people from the Baby Boomer generation, born between 1946 and 1964. The use of an artificial cut off age of 65 years of age as the definition of elderly or old is somewhat arbitrary and this will be discussed. The presentation will look at the prevalence of substance use among older people with an added focus on opioid epidemiology. It will also provide an overview for screening and identifying substance use within this population group. Additionally, a broad biopsychosocial framework and sociohistorical lens will be utilized to analyze risk factors and vulnerabilities for substance use among older people. The presentation will conclude with care considerations that integrate psychosocial aspects of well-being and reinforce the importance of psychotherapeutic interventions.
Clients in treatment for Opioid Use Disorders, particularly those in medication assisted treatment have been found to have extremely high rates of co-occurring gambling disorder. This online training will review the research on the co-occurrence of gambling disorder and opioid use disorder, focusing on both quantitative and qualitative research that has sought to understand this connection. Transcripts from clients in medication assisted treatment will be used to illustrate the role gambling plays in their lives and recoveries. Strategies for screening and treating gambling issues among those in treatment for opioid use disorders will be discussed.
This self-paced, online course offers an evidence based/informed review of buprenorphine vs methadone during pregnancy and recommendations for providers/organizations that treat pregnant, postpartum, and reproductive age patients.
This Training is designed to educate mandated reporters on opioid misuse and abuse and how to report to Nevada Adult Protective Services if you suspect abuse of vulnerable adults.
This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder.
This poster is for clients and their family members in OUD treatment who are pregnant or who are currently not pregnant but of childbearing age.
Nevada’s Substance Abuse Prevention and Treatment Agency (SAPTA) is housed under the Nevada Division of Public and Behavioral Health (DPBH) within the Department of Health and Human Services (DHHS). The Maternal, Child, and Adolescent Health (MCAH) program also resides within DPBH. MCH entities and providers have had a long-standing collaborative relationship with SAPTA, which has strengthened over the past two years with shifting substance use trends. Alcohol, tobacco, and opioids remain the most used substances in Nevada. Deaths involving synthetic opioids other than methadone (including fentanyl and fentanyl analogs) continue to rise to a rate of 9.9 per 100,000 individuals in 2018, while prescription opioid-related overdose deaths have declined to a rate of 4.6 (NIDA, 2020)
The Substance Abuse and Mental Health Services Administration (SAMHSA) administers the State Targeted Response to the Opioid Crisis (STR) and State Opioid Response (SOR) grant programs. These grants aim to address the opioid crisis by increasing access to treatment, reducing unmet treatment need, and reducing opioid overdose related deaths through the provision of prevention, treatment, and recovery activities for opioid use disorder (OUD) in the States. States received a total of $500 million for each of FY 2017 and FY 2018 through STR. Additionally, in FY 2018, States received an additional $1 billion in new funding through the SOR grants. In FY 2019, States received $1.5 billion through SOR. Eligible applicants for both STR and SOR are the State alcohol and drug agencies.
The Nevada State Targeted Response to the Opioid Crisis Strategic Plan was submitted to SAMHSA on December 21, 2018. The details of the plan can be found in the following document.
The needs assessment will inform decision making on how to best address the opioid crisis. The details of the needs assessment can be found in the following document.
In February 2018, a total of 1,074 healthcare providers responded to a needs assessment designed to guide development of opioid-related trainings to facilitate successful implementation of Nevada’s Opioid State Targeted Response.
A Nevada provider’s guide to prescribing Naloxone to patients who use opioids.
This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.
This report provides an update on the present state of coverage, availability of, and access to, medications for treating ongoing alcohol use disorder (AUD) and opioid use disorder (OUD) and reversing an opioid overdose within state Medicaid plans. It also includes examples of innovative efforts to increase access to medications for the treatment of SUDs.
The Division of Health Care Financing and Policy has taken action to address the opioid crisis by updating Nevada Medicaid policy and opening Medication-Assisted Treatment (MAT)-related evaluation and management (E/M) codes for billing by Nevada Medicaid providers effective with dates of service on or after January 1, 2020. In addition to MAT related E/M codes, Nevada Medicaid opened Screening, Brief Intervention, Referral to Treatment (SBIRT) codes to assist providers in performing screening services to recipients at risk or struggling with Substance Use Disorder (SUD).
This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.
This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder
The Addiction Technology Transfer Center (ATTC) Network Coordinating Office (NCO), funded by the Substance Abuse and Mental Health Services (SAMHSA), has designed three competency-based guides to raise awareness of resources available to build the capacity of the workforce to address the opioid crisis. The digital guides are relevant to psychologists, counselors, social workers, peer support workers, and other behavioral health professionals who intersect with people at risk for misuse of, or who are already misusing, opioids.
This pocket guide is designed as a quick reference for information about medication-assisted treatment for opioid use disorder. It offers a checklist for prescribing medications to patients and provides a list of approved medications for treatment.
A compilation of essays by individuals supported by Medication-Assisted Treatment in long-term recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
Includes graphs and tables on death rates, opioid-related emergency department visits and inpatient admissions, and opioid prescriptions at the county-level and zip code-level.
A dashboard to look at overdose death data for 2020 by substance for 29 states/jurisdictions.
A dashboard to look at emergency department non-fatal overdose data since February 2018 for all drugs, all opioids, heroin, or all stimulants by state.